IntroductionCenterforFutureTechnologies

inCancerCareCatherineKlapperich,Ph.D.

DirectorBostonUniversity

9June2016

NewTherapies

Linda McCulloch William Burhans Andrew Levy

Immunotherapy,BrainCancerRemission

TargetedTherapy,RemissionfromBRCA-positiveprostatecancer

Immunotherapy,LeukemiaRemission

PrecisionMedicine

• Whowillbenefitmostfromthesenewtherapies?• Howcanweimprovehealthcaredeliverytoimpactthemostpatients?

• Willthesenewtherapiesandtheircostworsenhealthdisparities?

“Precision medicine is not the future of cancer care, it is the present. This study reinforces that the more we personalize treatment to the patient and the tumor, the better the outcomes – even in the earliest phases of research,” said Don S. Dizon, MD, FACP.

PointofCareandtheNewCancerCare• Inordertoreducecosts,itwillbenecessarytohavethefollowinginformationaccessibletocliniciansandtheirpatients• Inexpensivesequencingdataofprimaryandmetastatictumors.

• Tumorsmonitoredmolecularlythroughoutthecourseoftreatment.

• Assessmentoftherapyearlierintreatment.Earlydetectionofnewacquiredmutationsthatmightenableresistance.

• Managementoftheseteststhroughoutthecourseofcare.• Hightouchpatientmanagementwithfewerofficevisits.• Puttingqualityoflifeissuesfrontandcenter.

DisparitiesinCancerCare

Documentedcancerhealthdisparitiesinclude:

• ahigherincidenceofaparticularlyaggressiveformofbreastcancer(thetriple-negativesubtype)amongAfricanAmericanwomenthanwomenofotherracial/ethnicgroups

• substantiallyhigherratesofprostatecancerincidenceanddeathamongAfricanAmericanmenthanmenofotherracial/ethnicgroups

• higherratesofkidneycanceramongAmericanIndianandAlaskaNativesthanotherracial/ethnicgroups

• higherratesoflivercanceramongAsianandPacificIslandersthanotherracial/ethnicgroups

• higherratesofcervicalcancerincidenceanddeathamongHispanicandAfricanAmericanwomenthanwomenofotherracial/ethnicgroups

GlobalDisparitiesinCancerCareAreastoaddressglobalhealthdisparitiesincancercareinclude:

• TobaccoControl• Obesity,DietandExercise• Vaccines• Prevention,EarlyDetection,Treatment• PalliativeCare

Meanstoaddressthesedisparities:• MobileHealthApplications• EMRs• PointofCareDiagnosisandRiskStratification• TreatmentMonitoring• QualityofLifeTechnologies

doi: 10.1200/JCO.2015.62.2860, JCO January 2016 vol. 34 no. 1 6-13

CFTCCisfocusedontheidentification,prototypingandearlyclinicalassessmentofinnovativepointofcaretechnologiesforthetreatment,screening,diagnosisandmonitoringofcancers.

Weaidinvestigatorsintheassessmentofearlystagetechnologiesintermsofclinicalneeds,marketdemandsandsettingappropriateness.

TheCenterhasasstrongemphasisonprototypingactivities.

Cancerdetectionandtreatmentisevolvingrapidly,andtheCFTCCstrivestokeeptestdevelopersontopofthechange.

!

Year 1 Year 2 Year 3 Year 4

Project #1Project #2

Project #3Project #4Project #5

Project #6Project #7Project #8Project #9

Project #10

Project #11

Project #12

Project #13

Project #14

Project #15

Project #16

Project #17

Year 5

Startup/Lic.

IndustryPartner VCFundingCFTCCFollowon

SummaryofPrototypeProjectstoDate

R21

R01BetaProt.

BetaProt.

BetaProt.

R21

HealthSystemFunds

PendingR01

IndustryPartner

BetaProt. IndustryPartner

Clin.TestACSandDODBetaProt.

R44

K22

Coulter$

R01 Startup/Lic

Fullpatentfiled BetaProt.inprog.

IndustryPartner

AdminCore

AlphaCore Funding BetaCore Transition

Prototyping

ProgressofProjectsThroughtheCenter

RFAProcess

Hackathons

Workshops

Symposia

SocialMedia

IndustryPartners

FederalFunding

Licensing

IPConsulting

RegulatoryConsulting

Startup

Press

LocatingClinicalSampleSets

TrainingCore

ClinicalNeedsCore

ScientificPublications

AlphaPrototypingCore

Equipment

• Microarray • Laser Cutter • Wax printer • Cutter Plotter• Real-Time PCR

System

• 3-D Printer • Desktop mill• Laminator • Stereomicroscope

• Class 1000 cleanroom • Precision Measurement Laboratory• EPIC machine shop• BSL 2 Lab Access

Other facilities

Stratasys uPrint SE Nikon SMZ18

FlexCircuit

ProbeHousing

Tumor(4.5cm)

A New Wearable Optical Probe for Chemotherapy Monitoring.Motivation

DiagnosisStage II/III

Locally Advanced

NeoadjuvantSystemic Therapy

Adapted from Zakhireh et al., 2008

Before

Chem

oA

fter C

hemo

Barrier:Adaptive Therapy Requires Better

Feedback

Our Solution:Wearable Diffuse Optical Imaging

Problem:It can take months to determine

chemosensitivity with current methods

Standard of Care

Pathologic Complete Response

PartialResponse

Non-Response

Months

Improved 5-year

survival

Little or no benefit toxic side-effects

broad chemoresistance

PI: Darren Roblyer, Boston University, Biomedical EngineeringCo-PI: Alexis Sauer-Budge, Fraunhofer CFI

The Wearable probe will be placed on the skin of a breast cancer patient over a known tumor location. Continuous measurements will be taken during chemotherapy infusions.

LEDs (750nm, 850nm)

Optical Sensor

The Wearable probe is designed to conform to breast

tissue.

It measures tumor metabolism during chemotherapy for early

response prediction.

CenterOutreach

Facebook

Twitter

Workshops and Training

Web Based Resources and Archives

CFTCC

@CFTCC_NIBIB@DrKlapperich

www.bu.edu/CFTCCwww.POCTRN.org

Photonics Center,BostonFraunhofer CMI

Alpha Prototyping Core